59.94
1.54%
0.91
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
7.15%
25.97
|
24.23 | 22.50 | 19.22 | 11.47 |
Cost Of Revenue |
13.18%
2.807
|
3.233 | 2.412 | 2.236 | 1.421 |
Gross Profit |
10.28%
23.16
|
21.00 | 20.09 | 16.98 | 10.05 |
Operating Expenses
|
161.86%
163.05
|
62.27 | 64.05 | 63.59 | 62.58 |
Interest Income/Expense |
4.51%
4.755
|
4.55 | 3.149 | 3.303 | 3.061 |
Benefits Costs and Expenses |
154.36%
167.04
|
65.67 | 66.30 | 65.83 | 63.65 |
Costs And Expenses |
153.22%
165.85
|
65.50 | 66.46 | 65.83 | 64.00 |
Operating Income/Loss |
239.00%
-139.89
|
-41.27 | -43.95 | -46.60 | -52.53 |
Nonoperating Income/Loss |
588.95%
-1.185
|
-0.172 | 0.158 | -0.099 | 0.352 |
Income/Loss From Continuing Operations Before Tax |
240.45%
-141.07
|
-41.44 | -43.80 | -46.70 | -52.18 |
Income Tax Expense/Benefit |
53.06%
0.30
|
0.196 | 0.368 | - | - |
Income/Loss From Continuing Operations After Tax |
239.57%
-141.37
|
-41.63 | -44.16 | -46.70 | -52.18 |
Net Income/Loss
|
239.57%
-141.37
|
-41.63 | -44.16 | -46.70 | -52.18 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
11,503%
60.14
|
0.5183 | 57.87 | 56.87 | 56.71 |
Basic Earnings Per Share |
235.71%
-2.35
|
-0.70 | -0.76 | -0.82 | -0.92 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):